Drug intelligence / Profile preview

AMP-01

Development stage: Preclinical
Lead developer: Reverb Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

AMP-01 is a bispecific antibody drug candidate developed by Reverb Therapeutics. It targets both interleukin-15 (IL-15) and programmed cell death protein 1 (PD-1), functioning as an inhibitor of these pathways. The primary therapeutic area under investigation for AMP-01 is neoplasms (cancers). As of the latest available information, its highest development phase is preclinical[3].

Targets

IL15 (Interleukin 15)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on AMP-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-01.

Explore the full profile